Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > Rivaroxaban and aspirin effective and safe for PAD patients

Rivaroxaban and aspirin effective and safe for PAD patients

Presented By
Prof. Marc Bonaca, University of Colorado, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACC 2020
Trial
VOYAGER PAD
Results from the VOYAGER PAD trial showed that rivaroxaban 5 mg (2.5 mg twice daily) + aspirin significantly reduced the risk of acute limb ischaemia and cardiovascular events in patients with symptomatic peripheral artery disease (PAD) after peripheral artery revascularisation [1]. Although there was a numerical increase in thrombolysis in myocardial infarction (TIMI) major bleeding and significantly increased International Society on Thrombosis and Haemostasis (ISTH) major bleeding, no excess was observed in intracranial or fatal bleeding. The multicentre, randomised, double-blind VOYAGER PAD trial was presented by Prof. Marc Bonaca (University of Colorado, USA), and simultaneously published in the New England Journal of Medicine [2]. The purpose of this trial was to investigate whether the benefits of a treat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on